NASDAQ: ASLN - ASLAN Pharmaceuticals Limited

Lønnsomhet i seks måneder: 0%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan ASLAN Pharmaceuticals Limited

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co.

flere detaljer
, Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2018-05-04
ISIN US04522R1014
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://aslanpharma.com
Цена ао 0.6
Prisendring per dag: 0% (0.6)
Prisendring per uke: 0% (0.6)
Prisendring per måned: 0% (0.6)
Prisendring over 3 måneder: 0% (0.6)
Prisendring over seks måneder: 0% (0.6)
Prisendring per år: -4% (0.625)
Prisendring over 3 år: -22.67% (0.7759)
Prisendring over 5 år: -72.09% (2.15)
Prisendring over 10 år: 0% (0.6)
Prisendring siden begynnelsen av året: 0% (0.6)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 4.41 4
P/BV -3.98 0
P/E 0 0
EV/EBITDA -1.35 0
Total: 4.25

Effektivitet

Navn Betydning Karakter
ROA, % -179.56 0
ROE, % 332.81 10
Total: 3.33

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.6183 10
Total: 9.6

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 4.45 1
Lønnsomhet Ebitda, % 2792.47 10
Lønnsomhet EPS, % 1015.89 10
Total: 8.2
Flere detaljer

Institusjoner Volum Dele, %
BVF Inc. 1049999 13.82
UBS Group AG 625000 8.23
Citadel Advisors Llc 482963 6.36
Shay Capital LLC 400000 5.26
Sio Capital Management, LLC 254150 3.34
Renaissance Technologies, LLC 172801 2.27
Parkman Healthcare Partners LLC 110658 1.46
Landscape Capital Management LLC 83259 1.1
Millennium Management LLC 80362 1.06
Waterfront Wealth, Inc. 40941 0.54



Veileder Stillingstittel Betaling Fødselsår
Dr. Carl Alan Jason Morton Firth EMBA, Ph.D. Founder, CEO & Executive Director N/A 1973 (52 år)
Mr. Kiran Kumar Asarpota COO & Head of Finance N/A 1979 (46 år)
Mr. Ben Goodger General Counsel N/A 1963 (62 år)
Mr. Stephen Doyle Chief Business Officer N/A 1973 (52 år)
Dr. Alexandre Kaoukhov M.D. Chief Medical Officer N/A 1974 (51 år)
Charlie Hsu Investor Relations Director N/A
Chi-Chin Wang IR & Corporate Development Director N/A

Adresse: Singapore, Singapore, 3 Temasek Avenue - åpne i Google maps, åpne Yandex-kart
Nettsted: https://aslanpharma.com